U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Tobramycin – Injection products
  1. Development Resources

Tobramycin – Injection products

Recognized Interpretive Criteria

FDA Identified Interpretive Criteria

 

Minimum Inhibitory
Concentrations

(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Enterobacterales

≤ 4

8

≥ 16

≥ 15

13-14

≤ 12

Pseudomonas aeruginosa

≤ 4

8

≥ 16

≥ 15

13-14

≤ 12

Staphylococcus aureus

≤ 4

8

≥ 16

≥ 15

13-14

≤ 12

S = Susceptible; I = Intermediate; R = Resistant

Exceptions to the recognized standard of CLSI M100

For the bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:

Acinetobacter spp.

Other Non-Enterobacterales

Back to Top